SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma trades higher on the BSE

20 Aug 2014 Evaluate

Ajanta Pharma is currently trading at Rs. 1592.00, up by 2.60 points or 0.16% from its previous closing of Rs. 1589.40 on the BSE.

The scrip opened at Rs. 1571.00 and has touched a high and low of Rs. 1607.00 and Rs. 1570.00 respectively. So far 2637 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 1798.45 on 05-Aug-2014 and a 52 week low of Rs. 475.33 on 28-Aug-2013.

Last one week high and low of the scrip stood at Rs. 1607.00 and Rs. 1450.00 respectively. The current market cap of the company is Rs. 5575.62 crore.

The promoters holding in the company stood at 73.55% while Institutions and Non-Institutions held 8.74% and 17.71% respectively.

Ajanta Pharma, a specialty focused pharmaceutical formulation company, has been listed on Forbes Asia's 'Best Under a Billion' 2014 list. This is the third consecutive listing of the company since 2012.

The ‘Best Under  A Billion’ list is published by Forbes Asia to recognize 200 small and midsized publicly listed companies in Asia Pacific region with annual revenue under $1 billion. The companies were selected based on three stringent categories of profitability, growth, and modest indebtedness from a universe of 17,000 stock-traded companies across Asia-Pacific region.

Ajanta Pharma is engaged in manufacturing pharmaceutical products. The company runs three divisions -- prescription drugs, OTC and institutional sales.

Ajanta Pharma Share Price

2767.15 -12.05 (-0.43%)
24-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1619.95
Dr. Reddys Lab 1315.85
Cipla 1294.75
Zydus Lifesciences 927.15
Lupin 2296.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×